Bard Financial Services Inc. Sells 1,357 Shares of Johnson & Johnson (NYSE:JNJ)

Bard Financial Services Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 116,944 shares of the company’s stock after selling 1,357 shares during the period. Johnson & Johnson makes up 1.5% of Bard Financial Services Inc.’s investment portfolio, making the stock its 13th biggest position. Bard Financial Services Inc.’s holdings in Johnson & Johnson were worth $19,357,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the stock. Peak Asset Management LLC increased its position in shares of Johnson & Johnson by 9.3% in the first quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock valued at $2,137,000 after acquiring an additional 1,171 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Johnson & Johnson by 0.9% in the first quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock valued at $116,071,000 after acquiring an additional 6,836 shares during the period. Vaughan Nelson Investment Management L.P. increased its position in shares of Johnson & Johnson by 21.8% during the first quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock valued at $140,050,000 after buying an additional 161,687 shares during the period. Tekla Capital Management LLC increased its position in shares of Johnson & Johnson by 12.8% during the first quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock valued at $111,876,000 after buying an additional 82,100 shares during the period. Finally, Wisconsin Capital Management LLC increased its position in shares of Johnson & Johnson by 0.8% during the first quarter. Wisconsin Capital Management LLC now owns 15,723 shares of the company’s stock valued at $2,437,000 after buying an additional 127 shares during the period. 68.40% of the stock is owned by institutional investors.

Insider Activity

In related news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider William Hait sold 14,698 shares of the stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several research analyst reports. TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday, August 21st. Stifel Nicolaus boosted their price objective on shares of Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. Wells Fargo & Company dropped their price objective on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research note on Thursday, August 31st. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 31st. Finally, Atlantic Securities boosted their price objective on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $170.65.

Johnson & Johnson Trading Up 0.6 %

NYSE:JNJ opened at $162.41 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The firm has a market cap of $422.10 billion, a P/E ratio of 32.88, a P/E/G ratio of 3.26 and a beta of 0.54. The firm has a 50-day simple moving average of $166.21 and a 200-day simple moving average of $161.83. Johnson & Johnson has a one year low of $150.11 and a one year high of $181.04.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.59 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.03 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were issued a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 2.93%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 96.36%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.